G. Chêne

发表

Use of a Bayesian approach to decide when to stop a therapeutic trial: the case of a chemoprophylaxis trial in human immunodeficiency virus infection.

R. Salamon, A. Kpozèhouen, P. Van de Perre, 2005, American journal of epidemiology.

Estimation of dynamical model parameters taking into account undetectable marker values

D. Commenges, H. Jacqmin-Gadda, D. Neau, 2006, BMC medical research methodology.

Health Data for Public Health: Towards New Ways of Combining Data Sources to Support Research Efforts in Europe

A. Barone, A. Burgun, E. Lettieri, 2017, Yearbook of Medical Informatics.

Incidence of Dementia over Three Decades in the Framingham Heart Study.

C. Dufouil, A. Beiser, V. Chouraki, 2016, The New England journal of medicine.

Cytokine and gene transcription profiles of immune responses elicited by HIV lipopeptide vaccine in HIV-negative volunteers

Y. Lévy, J. Lelièvre, H. Hocini, 2013, AIDS.

Validation of a risk-assessment scale and a risk-adapted monitoring plan for academic clinical research studies--the Pre-Optimon study.

Sylvie Chevret, Philippe Ravaud, Geneviève Chêne, 2011, Contemporary clinical trials.

Prognosis of HIV-1-infected patients starting highly active antiretroviral therapy: a collaborative analysis of prospective studies

Jonathan AC Sterne, Peter Reiss, Caroline A Sabin, 2002, The Lancet.

Week 96 efficacy of lopinavir/ritonavir monotherapy in virologically suppressed patients with HIV: a randomized non-inferiority trial (ANRS 140 DREAM)

C. Fagard, Y. Yazdanpanah, B. Spire, 2018, The Journal of antimicrobial chemotherapy.

Apport de l'épidémiologie clinique à la prise en charge de l'infection par le VIH

G. Chêne, P. Morlat, 1999 .

Comparative cost-effectiveness analysis of sacral anterior root stimulation for rehabilitation of bladder dysfunction in spinal cord injured patients.

B. Perrouin-Verbe, G. Chêne, A. Bénard, 2013, Neurosurgery.

High rate of virologic suppression with raltegravir plus etravirine and darunavir/ritonavir among treatment-experienced patients infected with multidrug-resistant HIV: results of the ANRS 139 TRIO trial.

C. Katlama, C. Fagard, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Neural correlates of episodic memory in the Memento cohort

B. Dubois, M. Chupin, J. Mangin, 2018, Alzheimer's & dementia.

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Is hepatitis C virus co-infection associated with survival in HIV-infected patients treated by combination antiretroviral therapy?

P. Couzigou, D. Neau, S. Lawson-Ayayi, 2002, AIDS.

Impact of Early versus Late Adherence to Highly Active Antiretroviral Therapy on Immuno-Virological Response: A 3-Year Follow-Up Study

J. Moatti, F. Raffi, M. Carrieri, 2002, Antiviral therapy.

Accelerating clinical development of HIV vaccine strategies: methodological challenges and considerations in constructing an optimised multi-arm phase I/II trial design

Y. Lévy, J. Lelièvre, R. Thiébaut, 2014, Trials.

Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.

H. Fleury, F. Raffi, C. Michelet, 2002, The Journal of infectious diseases.

Continuous versus intermittent treatment strategies during primary HIV-1 infection: the randomized ANRS INTERPRIM Trial

C. Rouzioux, G. Chêne, G. Pialoux, 2012, AIDS.

An additive/substractive genotypic score as a determinant of the virological response to didanosine in HIV-1 infected patients

B. Masquelier, J. Ragnaud, M. Dupon, 2006 .

High frequency of selection of K65R and Q151M mutations in HIV‐2 infected patients receiving nucleoside reverse transcriptase inhibitors containing regimen

F. Brun-Vézinet, D. Descamps, G. Chêne, 2004, Journal of medical virology.

Risk of Virological Failure in HIV-1-Infected Patients Experiencing Low-Level Viraemia under Active Antiretroviral Therapy (ANRS C03 Cohort Study)

P. Morlat, E. Lazaro, G. Chêne, 2015, Antiviral therapy.

Determinants of response to first HAART regimen in antiretroviral‐naïve patients with an estimated time since HIV seroconversion

H. Jacqmin-Gadda, C. Sabin, F. Dabis, 2006, HIV medicine.

1175 THE HEPATITIS C EPIDEMIC AMONG HIV-POSITIVE MEN WHO HAVE SEX WITH MEN: INCIDENCE ESTIMATES FROM 1990 TO 2007

R. Geskus, M. Prins, O. Hamouda, 2011 .

A. Mocroft, M. Egger, M. Prins, 2011, Blood.

Protozoan Diseases: Toxoplasmosis

R. Gilbert, R. Thiébaut, G. Chêne, 2008 .

In Vitro Phenotypic Susceptibility of Human Immunodeficiency Virus Type 2 Clinical Isolates to Protease Inhibitors

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, Antimicrobial Agents and Chemotherapy.

HIV-1 RNA response to antiretroviral treatment in 1280 participants in the Delta Trial: an extended virology study.

D. Jeffries, A. Breckenridge, F. Brun-Vézinet, 1999, AIDS.

Ten-year diabetes incidence in 1046 HIV-infected patients started on a combination antiretroviral treatment

C. Katlama, J. Capeau, F. Raffi, 2012, AIDS.

Optimal timing of antiretroviral treatment initiation in HIV-positive children and adolescents: a multiregional analysis from Southern Africa, West Africa and Europe.

D. Raben, F. Tanser, C. Chimbetete, 2016, International journal of epidemiology.

Recent developments in clinical trial designs for HIV vaccine research

C. Fagard, Y. Lévy, R. Thiébaut, 2015, Human vaccines & immunotherapeutics.

Immunological success is predicted by enfuvirtide but not interleukin-2 therapy in immunodepressed patients

C. Fagard, C. Rouzioux, Y. Lévy, 2009, AIDS.

Indinavir Plasma Concentration and Adherence Score Are Codeterminant of Early Virologic Response in HIV-Infected Patients of the APROCO Cohort

X. Panhard, F. Raffi, C. Leport, 2005, Therapeutic drug monitoring.

Indinavir Trough Concentration as a Determinant of Early Nephrolithiasis in HIV-1-Infected Adults

F. Raffi, F. Collin, G. Peytavin, 2007, Therapeutic drug monitoring.

Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d'Ivoire: a randomised trial

R. Salamon, S. Lafont, X. Anglaret, 1999, The Lancet.

CD4 cell recovery in treated HIV-2-infected adults is lower than expected: results from the French ANRS CO5 HIV-2 cohort

F. Brun-Vézinet, G. Peytavin, G. Chêne, 2006, AIDS.

Factors associated with clinical progression in HIV-2 infected-patients: The French ANRS cohort

R. Salamon, F. Brun-Vézinet, G. Chêne, 2003, AIDS.

Daily or three times per week interferon alpha-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C not responding to previous interferon alone.

V. de Lédinghen, P. Couzigou, H. Fleury, 2002, Journal of hepatology.

Daily or three times a week interferon alfa-2b in combination with ribavirin or interferon alone for the treatment of patients with chronic hepatitis C.

V. de Lédinghen, P. Couzigou, H. Fleury, 2002, Journal of Hepatology.

Changes in Causes of Death Among Adults Infected by HIV Between 2000 and 2005: The “Mortalité 2000 and 2005” Surveys (ANRS EN19 and Mortavic)

P. Morlat, D. Costagliola, C. Lewden, 2008, Journal of acquired immune deficiency syndromes.

Improved Sensitivity of Human Immunodeficiency Virus Type 2 Subtype B Plasma Viral Load Assay

F. Brun-Vézinet, D. Descamps, G. Chêne, 2005, Journal of Clinical Microbiology.

Interactions Between Amprenavir and the Lopinavir‐ritonavir Combination in Heavily Pretreated Patients Infected with Human Immunodeficiency Virus

F. Clavel, G. Chêne, C. Droz, 2004, Clinical pharmacology and therapeutics.

Are Trends in Dementia Incidence Associated With Compression in Morbidity? Evidence From The Framingham Heart Study

C. Dufouil, A. Beiser, S. Seshadri, 2018, The journals of gerontology. Series B, Psychological sciences and social sciences.

Role of Traditional Risk Factors and Antiretroviral Drugs in the Incidence of Chronic Kidney Disease, ANRS CO3 Aquitaine Cohort, France, 2004–2012

D. Neau, P. Morlat, E. Lazaro, 2013, PloS one.

Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis

J. Sterne, T. Sterling, M. May, 2013, AIDS.

Semantic loss marks early Alzheimer's disease‐related neurodegeneration in older adults without dementia

B. Dubois, M. Chupin, J. Mangin, 2020, Alzheimer's & dementia.

Dialyzer membrane permeability and survival in hemodialysis patients.

X. Leverve, P. Chauveau, C. Combe, 2005, American journal of kidney diseases : the official journal of the National Kidney Foundation.

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

R. Salamon, H. Ahiboh, C. Rouzioux, 2015, The New England journal of medicine.

Ritonavir-boosted darunavir combined with raltegravir or tenofovir–emtricitabine in antiretroviral-naive adults infected with HIV-1: 96 week results from the NEAT001/ANRS143 randomised non-inferiority trial

A. Antinori, F. Raffi, G. Chêne, 2014, The Lancet.

Clinical relevance of brain atrophy subtypes categorization in memory clinics

B. Dubois, M. Chupin, J. Mangin, 2020, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Effect of Dietary Supplementation With Lutein, Zeaxanthin, and &ohgr;-3 on Macular Pigment: A Randomized Clinical Trial

C. Creuzot-Garcher, M. Rougier, A. Bron, 2017, JAMA ophthalmology.

Comparison of Mycoplasma pneumoniae Infections in Asthmatic Children Versus Asthmatic Adults

P. Girodet, G. Chêne, C. Raherison, 2014, The Pediatric infectious disease journal.

Stimulation of the primary anti‐HIV antibody response by IFN‐α in patients with acute HIV‐1 infection

C. Rouzioux, P. Poignard, P. Lebon, 2008, Journal of leukocyte biology.

Changing Incidence and Risk Factors for Kaposi Sarcoma by Time Since Starting Antiretroviral Therapy: Collaborative Analysis of 21 European Cohort Studies.

M. Zwahlen, A. Mocroft, M. Egger, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

MEMENTO: A NATIONAL COHORT ON DETERMINANTS AND BIOMARKERS OF ALZHEIMER'S DISEASE AND ASSOCIATED DISORDERS

J. Pariente, O. Beauchet, F. Pasquier, 2014, Alzheimer's & Dementia.

Causes of Death in HIV-Infected Individuals with Immunovirologic Success in a National Prospective Survey.

P. Morlat, G. Chêne, F. Bonnet, 2017, AIDS research and human retroviruses.

Comparison of Kaposi Sarcoma Risk in Human Immunodeficiency Virus-Positive Adults Across 5 Continents: A Multiregional Multicohort Study

Sally S Bebawy, Richard D Moore, J. Margolick, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL?

A. Mocroft, O. Kirk, H. Furrer, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Emerging role of hepatocellular carcinoma among liver-related causes of deaths in HIV-infected patients: The French national Mortalité 2005 study.

P. Morlat, D. Costagliola, C. Lewden, 2009, Journal of hepatology.

P. Morlat, D. Costagliola, C. Lewden, 2009, HIV medicine.

Incidence and Risk Factors of HIV-Related Non-Hodgkin's Lymphoma in the era of Combination Antiretroviral Therapy: A European Multicohort Study

A. Mocroft, M. Egger, J. Lundgren, 2009, Antiviral therapy.

Factors Associated with Mortality in Human Immunodeficiency Virus Type 1–Infected Adults Initiating Protease Inhibitor–Containing Therapy: Role of Education Level and of Early Transaminase Level Elevation (APROCO–ANRS EP11 Study)

R. Salamon, L. Cuzin, F. Raffi, 2002 .

Evaluation of New Quantitative Assays for Diagnosis and Monitoring of Cytomegalovirus Disease in Human Immunodeficiency Virus-Positive Patients

D. Neau, H. Fleury, J. Pellegrin, 1999, Journal of Clinical Microbiology.

Incidence of acquired immunodeficiency syndrome (AIDS)-related Kaposi's sarcoma in the Aquitaine Cohort, France, 1988-1996. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

M. Dupon, F. Dabis, J. Pellegrin, 1998, International journal of epidemiology.

Ten-year incidence and risk factors of bone fractures in a cohort of treated HIV1-infected adults

P. Massip, F. Raffi, F. Collin, 2009, AIDS.

Magnetization Transfer Imaging Shows Tissue Abnormalities in the Reversible Penumbra

J. Orgogozo, C. Pachai, V. Dousset, 2007, Stroke.

Uncontrolled Viral Replication as a Risk Factor for Non-AIDS Severe Clinical Events in HIV-Infected Patients on Long-Term Antiretroviral Therapy: APROCO/COPILOTE (ANRS CO8) Cohort Study

M. Dupon, F. Raffi, C. Leport, 2009, Journal of acquired immune deficiency syndromes.

Role of uncontrolled HIV RNA and immunodeficiency in the occurrence of malignancy in HIV-infected patients in the cART era , ANRS CO 3 Aquitaine Cohort

A. Sasco, D. Neau, S. Lawson-Ayayi, 2009 .

Two-Year Observational Study in Patients Infected with Drug-Resistant HIV-1 and Treated with the Fusion Inhibitor Enfuvirtide: The ZOOM Cohort

G. Chêne, P. Girard, J. Meynard, 2011 .

Switch from zidovudine- to non-zidovudine-containing regimens is associated with modest haematological improvement and no obvious clinical benefit: a substudy of the ANRS 099 ALIZE trial.

Y. Lévy, F. Collin, C. Leport, 2008, The Journal of antimicrobial chemotherapy.

Tenofovir DF/emtricitabine and efavirenz combination therapy for HIV infection in patients treated for tuberculosis: the ANRS 129 BKVIR trial.

C. Fagard, O. Lortholary, E. Caumes, 2016, The Journal of antimicrobial chemotherapy.

Immunovirological response to triple nucleotide reverse-transcriptase inhibitors and ritonavir-boosted protease inhibitors in treatment-naive HIV-2-infected patients: The ACHIEV2E Collaboration Study Group.

F. Brun-Vézinet, A. Calmy, A. van Sighem, 2011, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lopinavir/ritonavir monotherapy versus current treatment continuation for maintenance therapy of HIV-1 infection: the KALESOLO trial.

J. Izopet, G. Chêne, S. Kolta, 2010, The Journal of antimicrobial chemotherapy.

A randomized trial of two-drug versus three-drug tenofovir-containing maintenance regimens in virologically controlled HIV-1 patients.

C. Katlama, C. Michelet, G. Chêne, 2009, The Journal of antimicrobial chemotherapy.

Effect of Baseline CD4 Cell Counts on the Clinical Significance of Short-Term Immunologic Response to Antiretroviral Therapy in Individuals With Virologic Suppression

Ross J. Harris, J. Sterne, A. Mocroft, 2009, Journal of acquired immune deficiency syndromes.

How does loss to follow‐up influence cohort findings on HIV infection? A joint analysis of the French hospital database on HIV, Mortalité 2000 survey and death certificates *

D. Costagliola, C. Lewden, G. Chêne, 2009, HIV medicine.

Explaining the association between social and lifestyle factors and cognitive functions: a pathway analysis in the Memento cohort

J. Pariente, M. Chupin, J. Mangin, 2022, Alzheimer's research & therapy.

Delayed HIV diagnosis and initiation of antiretroviral therapy: inequalities by educational level, COHERE in EuroCoord

O. Kirk, A. d’Arminio Monforte, M. Egger, 2014, AIDS.

Factors associated with mortality in human immunodeficiency virus type 1-infected adults initiating protease inhibitor-containing therapy: role of education level and of early transaminase level elevation (APROCO-ANRS EP11 study). The Antiprotéases Cohorte Agence Nationale de Recherches sur le SIDA

R. Salamon, L. Cuzin, F. Raffi, 2002, The Journal of infectious diseases.

Prognostic factors in adult community-acquired bacterial meningitis: a 4-year retrospective study

M. Dupon, D. Gruson, G. Chêne, 2007, European Journal of Clinical Microbiology & Infectious Diseases.

Raising standards in clinical research – The impact of the ECRIN data centre certification programme, 2011–2016

C. Ohmann, G. Chêne, S. Canham, 2017, Contemporary clinical trials communications.

Randomized Study of Noninferiority Comparing Prosthetic and Autologous Vein Above-Knee Femoropopliteal Bypasses.

G. Chêne, D. Midy, T. Reix, 2016, Annals of vascular surgery.

Prevention of Ebola virus disease through vaccination: where we are in 2018

D. Watson-Jones, P. Piot, Y. Yazdanpanah, 2018, The Lancet.

Higher rates of triple‐class virological failure in perinatally HIV‐infected teenagers compared with heterosexually infected young adults in Europe

A. Mocroft, D. Podzamczer, C. Sabin, 2016, HIV medicine.

Impact of Vital Status Investigation Procedures on Estimates of Survival in Cohorts of HIV-Infected Patients From Sub-Saharan Africa

R. Salamon, C. Seyler, X. Anglaret, 2004, Journal of acquired immune deficiency syndromes.

Platelet function point-of-care tests in post-bypass cardiac surgery: are they relevant?

D. Ekouevi, G. Chêne, A. Coiffic, 2002, British journal of anaesthesia.

Impact of body weight on virological and immunological responses to efavirenz-containing regimens in HIV-infected, treatment-naive adults

A. Mocroft, C. Sabin, M. Battegay, 2015, AIDS.

Adiponectin and leptin in Afro-Caribbean men and women with HIV infection: association with insulin resistance and type 2 diabetes.

J. Capeau, J. Bastard, G. Chêne, 2011, Diabetes & metabolism.

Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol.

P. Morlat, D. Costagliola, C. Lewden, 2005, Journal of hepatology.

P. Morlat, D. Costagliola, G. Chêne, 2015, HIV medicine.

Long-Lasting Persistence of Integrase Resistance Mutations in HIV-2-Infected Patients after Raltegravir Withdrawal

C. Charpentier, F. Brun-Vézinet, O. Delelis, 2011, Antiviral therapy.

Saline spa water or combined water and UV-B for psoriasis vs conventional UV-B: lessons from the Salies de Béarn randomized study.

A. Taïeb, G. Chêne, C. Cazenave, 2001, Archives of dermatology.

Acquired immunodeficiency syndrome-associated Kaposi's sarcoma and human herpesvirus 8 DNA detection in serial peripheral blood mononuclear cell samples.

B. Masquelier, J. Ragnaud, M. Dupon, 1997, Research in virology.

Quality Control Assessment of Human Immunodeficiency Virus Type 2 (HIV-2) Viral Load Quantification Assays: Results from an International Collaboration on HIV-2 Infection in 2006

F. Brun-Vézinet, B. Rodés, J. Albert, 2008, Journal of Clinical Microbiology.

The effect of Depressive Symptoms at ART Initiation on HIV Clinical Progression and Mortality: Implications in Clinical Practice

M. Carrieri, C. Leport, B. Spire, 2007, Antiviral therapy.

Inter‐ and intraobserver reliability of five MRI sequences in the evaluation of the final volume of cerebral infarct

J. Orgogozo, C. Pachai, V. Dousset, 2009, Journal of magnetic resonance imaging : JMRI.

Pravastatin in HIV-Infected Patients Treated with Protease Inhibitors: A Placebo-Controlled Randomized Study

D. Breilh, P. Morlat, F. Dabis, 2007, HIV clinical trials.

Efficacy and safety of varenicline for smoking cessation in people living with HIV in France (ANRS 144 Inter-ACTIV): a randomised controlled phase 3 clinical trial.

C. Katlama, C. Fagard, B. Spire, 2018, The lancet. HIV.

Bacterial Pneumonia among HIV-Infected Patients: Decreased Risk After Tobacco Smoking Cessation. ANRS CO3 Aquitaine Cohort, 2000–2007

D. Neau, M. Dupon, F. Dabis, 2010, PloS one.

New insights into childhood autoimmune hemolytic anemia: a French national observational study of 265 children

A. Fischer, A. Baruchel, G. Leverger, 2011, Haematologica.

Effectiveness of prenatal treatment for congenital toxoplasmosis: a meta-analysis of individual patients' data

R. Gilbert, R. Thiébaut, G. Chêne, 2007, The Lancet.

Incidence and risk factors of bacterial pneumonia requiring hospitalization in HIV‐infected patients started on a protease inhibitor‐containing regimen

L. Cuzin, F. Raffi, G. Chêne, 2006, HIV medicine.

Imatinib mesylate in scleroderma‐associated diffuse skin fibrosis: a phase II multicentre randomized double‐blinded controlled trial

S. Lepreux, E. Hachulla, S. Prey, 2012, The British journal of dermatology.

Methodological issues of non-inferiority trials in HIV-infected patients: a need for consensus?

R. Thiébaut, G. Chêne, L. Richert, 2008, AIDS.

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

Bone marrow histopathologic and molecular staging in epidermotropic T-cell lymphomas.

P. Dubus, J. Merlio, M. Beylot-Barry, 2003, American journal of clinical pathology.

Evidence that an identical T cell clone in skin and peripheral blood lymphocytes is an independent prognostic factor in primary cutaneous T cell lymphomas.

P. Dubus, J. Merlio, M. Beylot-Barry, 2001, The Journal of investigative dermatology.

Pharmacokinetics of etravirine , raltegravir and darunavir / ritonavir in treatment experienced patients

C. Katlama, C. Fagard, Y. Yazdanpanah, 2010 .

Clinically informative measures of the effect of drugs or other interventions.

R. Salamon, S. Suissa, L. Salmi, 2008, British journal of clinical pharmacology.

No association between GB virus C infection and disease progression in HIV-2-infected patients from the French ANRS HIV-2 cohort

F. Brun-Vézinet, D. Descamps, G. Chêne, 2006, AIDS.

Interaction between HIV-1 and HCV infections: towards a new entity?

F. Dabis, G. Chêne, M. Winnock, 2004, The Journal of antimicrobial chemotherapy.

Hepatitis B or Hepatitis C Virus Infection Is a Risk Factor for Severe Hepatic Cytolysis after Initiation of a Protease Inhibitor-Containing Antiretroviral Regimen in Human Immunodeficiency Virus-Infected Patients

P. Morlat, F. Raffi, C. Leport, 2000, Antimicrobial Agents and Chemotherapy.

[Human immunodeficiency virus infection and AIDS in Aquitaine. 10 years' experience of a hospital information system, 1985-1995. Le Groupe d'Epidemiologie Clinique du SIDA en Aquitaine (GECSA)].

R. Salamon, F. Dabis, G. Chêne, 1997, Presse medicale.

Survival after AIDS-defining events in patients with < 200 lymphocytes CD4+ x 10(6)/L who are toxoplasmosis antibody positive. ANRS 005/ACTG 154 Trial Group.

R. Salamon, B. Luft, P. Morlat, 1997, Journal of acquired immune deficiency syndromes and human retrovirology : official publication of the International Retrovirology Association.

Selection of K65R Mutation in HIV-2-Infected Patients Receiving Tenofovir-Containing Regimen

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2004, Antiviral therapy.

Methods for summarizing the risk associations of quantitative variables in epidemiologic studies in a consistent form.

S G Thompson, S. Thompson, G. Chêne, 1996, American journal of epidemiology.

Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe

A. Mocroft, O. Kirk, C. Sabin, 2017, AIDS.

Children and young people with perinatal HIV in Europe: epidemiological situation in 2014 and implications for the future

M. Sandhu, O. Kirk, M. Rosińska, 2016 .

Survey of European programmes for the epidemiological surveillance of congenital toxoplasmosis.

R. Salamon, R. Gilbert, L. Salmi, 2008, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

New molecular assays to predict occurrence of cytomegalovirus disease in renal transplant recipients.

H. Fleury, D. Ekouevi, G. Chêne, 2000, The Journal of infectious diseases.

About the necessity to manage events coded with MedDRA prior to statistical analysis: proposal of a strategy with application to a randomized clinical trial, ANRS 099 ALIZE.

F. Collin, G. Chêne, J. Molina, 2008, Contemporary clinical trials.

Prognostic importance of anaemia in HIV type-1-infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies.

Ross J. Harris, J. Sterne, A. Mocroft, 2008, Antiviral therapy.

Association of soluble CD14 and inflammatory biomarkers with HIV-2 disease progression.

C. Charpentier, F. Brun-Vézinet, J. Capeau, 2012, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

A. Mocroft, H. Günthard, R. Paredes, 2010, Archives of internal medicine.

Incidence of cytomegalovirus disease in the Aquitaine cohort of HIV-infected patients: a retrospective survey, 1987-1993. Groupe d'Epidémilogie Clinique du SIDA en Aquitaine (GECSA).

J. Ragnaud, P. Morlat, F. Dabis, 1997, Journal of Infection.

Predictors of CD4(+) T-cell counts of HIV type 1-infected persons after virologic failure of all 3 original antiretroviral drug classes.

A. Mocroft, H. Günthard, D. Podzamczer, 2013, The Journal of infectious diseases.

Early control of HIV replication in primary HIV-1 infection treated with antiretroviral drugs and pegylated IFN alpha: results from the Primoferon A (ANRS 086) Study.

C. Rouzioux, G. Chêne, J. Molina, 2001, AIDS.

Impact of low-level viremia on clinical and virological outcomes in treated HIV-1-infected patients.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, AIDS.

Options for clinical trials of pre and post-natal treatments for congenital toxoplasmosis.

R. Thiébaut, G. Chêne, 2009, Memorias do Instituto Oswaldo Cruz.

Reference curves for CD4 T‐cell count response to combination antiretroviral therapy in HIV‐1‐infected treatment‐naïve patients

A. Mocroft, A. d’Arminio Monforte, C. Sabin, 2017, HIV medicine.

Reference curves for CD 4 T-cell count response to combination antiretroviral therapy in HIV-1-infected treatment-na € ı ve patients

A. Mocroft, C. Sabin, M. Battegay, 2016 .

No Positive Association between Vitamin D Level and Immune Responses to Hepatitis B and Streptococcus pneumoniae Vaccination in HIV-Infected Adults

F. Carrat, Y. Lévy, J. Souberbielle, 2016, PloS one.

Quantitation of Hepatitis C Virus RNA in Plasma and Peripheral Blood Mononuclear Cells of Patients with Chronic Hepatitis Treated with Interferon-α

V. de Lédinghen, P. Couzigou, H. Fleury, 2004, Digestive Diseases and Sciences.

Prodromal characteristics of dementia with Lewy bodies: baseline results of the MEMENTO memory clinics nationwide cohort

M. Chupin, F. Pasquier, J. Dartigues, 2022, Alzheimer's research & therapy.

Prodromal characteristics of Dementia with Lewy Bodies: baseline results of the Memento nationwide cohort

M. Chupin, F. Pasquier, J. Dartigues, 2022 .

Role of long-term nucleoside-analogue therapy in lipodystrophy and metabolic disorders in human immunodeficiency virus-infected patients.

P. Morlat, F. Raffi, G. Chêne, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Causes of death among HIV‐infected patients in the era of highly active antiretroviral therapy, Bordeaux, France, 1998–1999

D. Neau, P. Morlat, F. Djossou, 2002, HIV medicine.

Role of Long-Term Nucleoside-Analogue Therapy in Lipodystrophy and Metabolic Disorders in Human Immunodeﬁciency Virus–Infected Patients

P. Morlat, F. Raffi, G. Chêne, 2002 .

Increase of atherogenic plasma profile in HIV-infected patients treated with protease inhibitor-containing regimens.

P. Morlat, G. Chêne, F. Bonnet, 2000, Journal of acquired immune deficiency syndromes.

In vitro Phenotypic Susceptibility to Nucleoside Reverse Transcriptase Inhibitors of HIV-2 Isolates with the Q151M Mutation in the Reverse Transcriptase Gene

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2005, Antiviral therapy.

Associations among hypertension, dementia biomarkers, and cognition: The MEMENTO cohort

M. Chupin, C. Annweiler, C. Dufouil, 2022, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Selection of the Q148R integrase inhibitor resistance mutation in a failing raltegravir containing regimen.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, AIDS.

Viremia Copy-Years as a Predictive Marker of All-Cause Mortality in HIV-1–Infected Patients Initiating a Protease Inhibitor–Containing Antiretroviral Treatment

B. Hoen, J. Cassuto, F. Raffi, 2015, Journal of acquired immune deficiency syndromes.

Prognostic importance of anaemia in HIV-1 infected patients starting antiretroviral therapy: collaborative analysis of prospective cohort studies in industrialized countries

J. Sterne, A. Mocroft, M. Egger, 2015 .

Neutralizing antibodies to interferon‐α and circulating interferon in patients with chronic hepatitis C non‐responding to pegylated interferon plus ribavirin re‐treated by pegylated interferon‐α‐2a and ribavirin (ANRS HC16 GAMMATRI substudy*)

P. Couzigou, P. Marcellin, G. Chêne, 2010, Journal of medical virology.

Cellular CD4 T cell responses to the diphtheria-derived carrier protein of conjugated pneumococcal vaccine and antibody response to pneumococcal vaccination in HIV-infected adults.

C. Katlama, Y. Lévy, G. Chêne, 2010, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Lessons from an unpleasant surprise: a biochemical strategy for the diagnosis of pheochromocytoma

D. Ducassou, A. Tabarin, J. Corcuff, 2001, Journal of hypertension.

Response to combination antiretroviral therapy: variation by age

A. d’Arminio Monforte, C. Sabin, M. Battegay, 2008, AIDS.

Clinical, biologic, and behavioral predictors of early immunologic and virologic response in HIV-infected patients initiating protease inhibitors.

R. Salamon, B. Masquelier, J. Moatti, 2001 .

Clinical, Biologic, and Behavioral Predictors of Early Immunologic and Virologic Response in HIV‐Infected Patients Initiating Protease Inhibitors

R. Salamon, B. Masquelier, J. Moatti, 2001, Journal of acquired immune deficiency syndromes.

Immunoblot Proﬁle as Predictor of Toxoplasmic Encephalitis in Patients Infected with Human Immunodeﬁciency Virus

J. Miro, B. Luft, P. Morlat, 2001 .

Cellular CD 4 T Cell Responses to the Diphtheria-Derived Carrier Protein of Conjugated Pneumococcal Vaccine and Antibody Response to Pneumococcal Vaccination in HIV-Infected Adults

C. Katlama, Y. Lévy, G. Chêne, 2010 .

CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study

C. Morrison, F. Brun-Vézinet, F. Dabis, 2017, The Journal of antimicrobial chemotherapy.

Comparison of viro-immunological marker changes between HIV-1 and HIV-2-infected patients in France

F. Brun-Vézinet, F. Dabis, E. Lazaro, 2008, AIDS.

Editorial Manager(tm) for Aids Manuscript Draft Title: Comparison of Viro-immunologic Markers Changes between Hiv-1 and Hiv-2 Infected Patients In

F. Brun-Vézinet, F. Dabis, E. Lazaro, 2022 .

Predictors of long-term increase in CD4(+) cell counts in human immunodeficiency virus-infected patients receiving a protease inhibitor-containing antiretroviral regimen.

H. Fleury, F. Raffi, C. Michelet, 2002, The Journal of infectious diseases.

Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial.

A. Mocroft, C. Katlama, P. Reiss, 2015, The lancet. HIV.

The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007

R. Geskus, M. Prins, O. Hamouda, 2011, AIDS.

Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS.

P. Morlat, D. Costagliola, C. Lewden, 2004, International journal of epidemiology.

Association of APOE ε4 with cerebral gray matter volumes in non-demented older adults: The MEMENTO cohort study

M. Chupin, C. Dufouil, S. Sabia, 2022, NeuroImage.

Diabetes mellitus and cognition: A pathway analysis in the MEMENTO cohort

M. Chupin, C. Annweiler, F. Pasquier, 2022 .

Diabetes mellitus and cognition: A pathway analysis in the MEMENTO cohort

M. Chupin, C. Annweiler, F. Pasquier, 2021 .

Prevalence and underestimation of pain in HIV-infected patients by physicians: a cross-sectional study in a day care hospital.

P. Morlat, G. Chêne, D. Lacoste, 1999, AIDS.

Self-reported side-effects of anti-retroviral treatment among IDUs: a 7-year longitudinal study (APROCO-COPILOTE COHORT ANRS CO-8).

F. Raffi, M. Carrieri, C. Protopopescu, 2007, The International journal on drug policy.

Sudden cardiac arrest associated with early repolarization.

Thomas Lavergne, Nicolas Derval, Michel Haïssaguerre, 2008, The New England journal of medicine.

Genome-wide meta-analysis for Alzheimer’s disease cerebrospinal fluid biomarkers

W. M. van der Flier, D. Rujescu, I. Giegling, 2022, Acta Neuropathologica.

Diabetes and cognitive decline in a French cohort of patients infected with HIV-1

H. Amièva, J. Dartigues, C. Dufouil, 2015, Neurology.

The Dementias Platform UK (DPUK) Data Portal

Ronan A Lyons, Matthew South, Paul M. Matthews, 2019, bioRxiv.

Interferon-ribavirin in association with stavudine has no impact on plasma human immunodeficiency virus (HIV) type 1 level in patients coinfected with HIV and hepatitis C virus: a CORIST-ANRS HC1 trial.

F. Zoulim, P. Morlat, P. Sogni, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Increased risk of toxoplasmic encephalitis in human immunodeficiency virus-infected patients with pyrimethamine-related rash. ANRS 005-ACTG 154 Trial Group. Agence Nationale de Recherche sur le SIDA (ANRS-INSERM) and the NIAID-AIDS Clinical Trials Group.

R. Salamon, B. Luft, P. Morlat, 1997, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Trends and determinants of severe morbidity in HIV‐infected patients: the ANRS CO3 Aquitaine Cohort, 2000–2004 *

S. Lawson-Ayayi, M. Dupon, P. Morlat, 2007, HIV medicine.

Evolving epidemiology of malignancies in HIV

G. Chêne, F. Bonnet, 2008, Current opinion in oncology.

Skin colonization by Malassezia species in neonates: a prospective study and relationship with neonatal cephalic pustulosis.

F. Weill, A. Taïeb, G. Chêne, 2002, Archives of dermatology.

Cohort Profile: Collaboration of Observational HIV Epidemiological Research Europe (COHERE) in EuroCoord.

J. Sterne, A. Mocroft, A. d’Arminio Monforte, 2016, International journal of epidemiology.

Long-term outcome of AIDS-associated cryptococcosis in the era of combination antiretroviral therapy

M. Alvarez, F. Dromer, O. Lortholary, 2006, AIDS.

Long-term virological suppression on first-line efavirenz + tenofovir + emtricitabine/lamivudine for HIV-1

J. Sterne, F. Ceccherini‐Silberstein, C. Sabin, 2019, AIDS.

Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs

Richard D Moore, K. Anastos, O. Kirk, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia.

M. Zwahlen, M. Egger, B. Eley, 2016, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

The incidence of AIDS-defining illnesses at a current CD4 count ≥ 200 cells/μL in the post-combination antiretroviral therapy era.

B. Gazzard, A. Mocroft, O. Kirk, 2013, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE)

Anne M Johnson, Hansjakob Furrer, Peter Reiss, 2013, PLoS medicine.

CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE

B. Gazzard, O. Kirk, H. Furrer, 2012, PLoS medicine.

Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study.

A. Mocroft, D. Podzamczer, A. Phillips, 2012, The Lancet. Infectious diseases.

Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe

A. Mocroft, D. Podzamczer, A. Phillips, 2011, Journal of acquired immune deficiency syndromes.

Risk of triple-class virological failure in children with HIV: a retrospective cohort study

A. Phillips, D. Costagliola, D. Gibb, 2011, The Lancet.

Prognosis of HIV-associated non-Hodgkin lymphoma in patients starting combination antiretroviral therapy

A. Mocroft, M. Egger, J. Lundgren, 2009, AIDS.

Effectiveness of health education on Toxoplasma-related knowledge, behaviour, and risk of seroconversion in pregnancy.

R. Gilbert, G. Chêne, V. Leroy, 2008, European journal of obstetrics, gynecology, and reproductive biology.

[Causes of death among HIV infected adults in French Guyana and the French West Indies in the era of highly active antiretroviral therapy (HAART)].

P. Morlat, P. Couppié, C. Lewden, 2004, Medecine et maladies infectieuses.

Prognostic Importance of Anaemia in HIV Type-1-Infected Patients Starting Antiretroviral Therapy: Collaborative Analysis of Prospective Cohort Studies

Ross J. Harris, J. Sterne, A. Mocroft, 2008, Antiviral Therapy.

Impact of colony-stimulating factor therapy on clinical outcome and frequency rate of nosocomial infections in intensive care unit neutropenic patients

J. Reiffers, D. Gruson, G. Chêne, 2000, Critical care medicine.

Utility of fiberoptic bronchoscopy in neutropenic patients admitted to the intensive care unit with pulmonary infiltrates

D. Gruson, G. Chêne, G. Gbikpi-Benissan, 2000, Critical care medicine.

Use of efavirenz is not associated with a higher risk of depressive disorders: a substudy of the randomized clinical trial ALIZE-ANRS 099.

J. Cassuto, G. Chêne, J. Molina, 2006, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Effect of abacavir on sustained virologic response to HCV treatment in HIV/HCV co-infected patients, Cohere in Eurocoord

D. Raben, J. Rockstroh, F. Dabis, 2015, BMC Infectious Diseases.

Once-daily combination therapy with emtricitabine, didanosine, and efavirenz in human immunodeficiency virus-infected patients.

P. Morlat, W. Rozenbaum, F. Raffi, 2000, The Journal of infectious diseases.

Pharmacokinetics of emtricitabine, didanosine and efavirenz administered once‐daily for the treatment of HIV‐infected adults (pharmacokinetic substudy of the ANRS 091 trial) *

W. Rozenbaum, G. Peytavin, G. Chêne, 2004, HIV medicine.

Incidence of and risk factors for adverse drug reactions in a prospective cohort of HIV-infected adults initiating protease inhibitor-containing therapy.

R. Salamon, M. Dupon, P. Morlat, 2004, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Predictors of virological rebound in HIV-1-infected patients initiating a protease inhibitor-containing regimen

F. Brun-Vézinet, J. Moatti, J. Cassuto, 2002, AIDS.

Occult hepatitis B in HIV-HCV coinfected patients

C. Leport, G. Chêne, A. Gervais, 2008, Scandinavian journal of infectious diseases.

Four year follow-up of simplification therapy with once-daily emtricitabine, didanosine and efavirenz in HIV-infected patients (ALIZE ANRS 099 trial).

P. Morlat, W. Rozenbaum, G. Chêne, 2011, The Journal of antimicrobial chemotherapy.

Five-Year Follow up of Once-Daily Therapy with Emtricitabine, Didanosine and Efavirenz (Montana ANRS 091 Trial)

P. Morlat, F. Raffi, G. Chêne, 2006, Antiviral therapy.

The adherence to antiretroviral treatment evaluated from a hospital pharmacy: importance of the protease inhibitors pharmacological class

S. Pédeboscq, D. Ekouevi, G. Chêne, 2005, International journal of STD & AIDS.

Simplification therapy with once-daily emtricitabine, didanosine, and efavirenz in HIV-1-infected adults with viral suppression receiving a protease inhibitor-based regimen: a randomized trial.

P. Morlat, W. Rozenbaum, F. Collin, 2005, The Journal of infectious diseases.

Predictive Values of the Human Immunodeficiency Virus Phenotype and Genotype and of Amprenavir and Lopinavir Inhibitory Quotients in Heavily Pretreated Patients on a Ritonavir-Boosted Dual-Protease-Inhibitor Regimen

F. Clavel, G. Chêne, A. Barrail-Tran, 2008, Antimicrobial Agents and Chemotherapy.

Rates of disease progression according to initial highly active antiretroviral therapy regimen: a collaborative analysis of 12 prospective cohort studies.

J. Sterne, M. Egger, R. Hogg, 2006, The Journal of infectious diseases.

Causes of death among HIV-infected patients in France in 2010 (national survey): trends since 2000

P. Morlat, D. Costagliola, G. Chêne, 2014, AIDS.

Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.

C. Sabin, R. Geskus, M. Prins, 2013, Gastroenterology.

Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy

C. Sabin, V. Rondeau, M. Prins, 2009, AIDS.

Comparison of genotypic and phenotypic resistance patterns of human immunodeficiency virus type 1 isolates from patients treated with stavudine and didanosine or zidovudine and lamivudine.

F. Clavel, G. Chêne, J. Molina, 2001, The Journal of infectious diseases.

Immunological efficacy of a prime-boost pneumococcal vaccination in HIV-infected adults

C. Katlama, Y. Lévy, G. Chêne, 2007, AIDS.

Clinical efficacy of antiretroviral combination therapy based on protease inhibitors or non-nucleoside analogue reverse transcriptase inhibitors: indirect comparison of controlled trials

M. Zwahlen, M. Egger, Y. Yazdanpanah, 2004, BMJ : British Medical Journal.

Long-term nonprogressors and elite controllers in the ANRS CO5 HIV-2 cohort

F. Brun-Vézinet, B. Autran, R. Thiébaut, 2011, AIDS.

HIV-2 integrase gene polymorphism and phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitors raltegravir and elvitegravir in vitro.

F. Brun-Vézinet, G. Peytavin, D. Descamps, 2008, The Journal of antimicrobial chemotherapy.

Differences in proviral DNA load between HIV-1- and HIV-2-infected patients

F. Brun-Vézinet, G. Chêne, V. Lemée, 2008, AIDS.

Discontinuation of maintenance therapy for cytomegalovirus retinitis in HIV-infected patients receiving highly active antiretroviral therapy

C. Tural, G. Carcelain, R. Tubiana, 2001, AIDS.

AIDS and non-AIDS severe morbidity associated with hospitalizations among HIV-infected patients in two regions with universal access to care and antiretroviral therapy, France and Brazil, 2000–2008: hospital-based cohort studies

F. Dabis, C. Greib, V. Veloso, 2014, BMC Infectious Diseases.

C. Katlama, J. Moatti, C. Leport, 2003, Journal of acquired immune deficiency syndromes.

J. Ragnaud, W. Rozenbaum, J. Capeau, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Raltegravir for the treatment of patients co-infected with HIV and tuberculosis (ANRS 12 180 Reflate TB): a multicentre, phase 2, non-comparative, open-label, randomised trial.

C. Delaugerre, C. Fagard, V. Veloso, 2014, The Lancet. Infectious diseases.

Comparison of B-mode ultrasound and computed tomography in the diagnosis of maxillary sinusitis in mechanically ventilated patients

D. Gruson, G. Chêne, G. Gbikpi-Benissan, 2001, Critical care medicine.

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

F. Brun-Vézinet, B. Autran, G. Peytavin, 2009, AIDS.

Women and HIV infection: a cohort study of 483 HIV-infected women in Bordeaux, France, 1985-1991. The Groupe d'Epidémiologie Clinique du SIDA en Aquitaine.

J. Ragnaud, M. Dupon, P. Morlat, 1992, AIDS.

Intrahepatic HCV RNA loads in 37 HIV‐HCV co‐infected patients with controlled HIV infection

D. Neau, J. Ragnaud, M. Dupon, 2002, Journal of medical virology.

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Nick C Fox, Catherine A. Macleod, W. M. van der Flier, 2022, Nature Genetics.

Common variants in Alzheimer’s disease and risk stratification by polygenic risk scores

W. M. van der Flier, M. Fornage, D. Rujescu, 2021, Nature Communications.

Role of uncontrolled HIV RNA level and immunodeficiency in the occurrence of malignancy in HIV-infected patients during the combination antiretroviral therapy era: Agence Nationale de Recherche sur le Sida (ANRS) CO3 Aquitaine Cohort.

A. Sasco, D. Neau, S. Lawson-Ayayi, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Peroxisome proliferator activating receptor alpha and gamma polymorphisms and metabolic abnormalities in HIV-infected patients receiving highly active antiretroviral therapy: the ANRS CO8 APROCO-COPILOTE study.

F. Raffi, C. Leport, G. Chêne, 2012, AIDS research and human retroviruses.

Fresh‐frozen plasma transfusion did not reduce 30‐day mortality in patients undergoing cardiopulmonary bypass cardiac surgery with excessive bleeding: the PLASMACARD multicenter cohort study

V. Rondeau, B. Rozec, G. Chêne, 2014, Transfusion.

É. Oksenhendler, P. Morlat, D. Costagliola, 2015, PloS one.

Transformation of mycosis fungoides: clinicopathological and prognostic features of 45 cases. French Study Group of Cutaneious Lymphomas.

T. Petrella, L. Vaillant, P. Courville, 2000, Blood.

Hot Spots of Integrase Genotypic Changes Leading to HIV-2 Resistance to Raltegravir

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2010, Antimicrobial Agents and Chemotherapy.

Long-term results and prognostic factors in patients with epithelial ovarian cancer.

G. Chêne, J. Saurel, A. Feyler, 2000, Gynecologic oncology.

Clinical progression of HIV-1 infection according to the viral response during the first year of antiretroviral treatment

H Jacqmin-Gadda, R Thiébaut, F Dabis, 2000, AIDS.

Enhanced T cell recovery in HIV-1-infected adults through IL-7 treatment.

C. Rouzioux, Y. Lévy, J. Lelièvre, 2009, The Journal of clinical investigation.

First-line Raltegravir/Emtricitabine/Tenofovir Combination in Human Immunodeficiency Virus Type 2 (HIV-2) Infection: A Phase 2, Noncomparative Trial (ANRS 159 HIV-2)

C. Charpentier, F. Brun-Vézinet, R. Tubiana, 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

In-vitro phenotypic susceptibility of HIV-2 clinical isolates to the integrase inhibitor S/GSK1349572

C. Charpentier, F. Brun-Vézinet, R. Schinazi, 2010, AIDS.

Biomarkers of CD4+ T-cell activation as risk factors for tuberculosis-associated immune reconstitution inflammatory syndrome

O. Lortholary, G. Chêne, L. Chakrabarti, 2014, AIDS.

Prognostic importance of initial response in HIV-1 infected patients starting potent antiretroviral therapy: analysis of prospective studies

J. Sterne, A. d’Arminio Monforte, M. Egger, 2003, The Lancet.

Cognitive disorders in HIV-infected patients: are they HIV-related?

H. Amièva, J. Dartigues, D. Neau, 2013, AIDS.

Prospective cohort study of the effect of pregnancy on the progression of human immunodeficiency virus infection. The Groupe d'Epidémiologie Clinique Du SIDA en Aquitaine.

P. Morlat, F. Dabis, G. Chêne, 1995, Obstetrics and gynecology.

[Incidence, risk factors and adequation of early readmission among the elderly].

P. Barberger‐Gateau, K. Pérès, M. Rainfray, 2002, Revue d'epidemiologie et de sante publique.

P. Morlat, D. Costagliola, C. Lewden, 2005, Cancer.

Chronic urticaria and Toxocara canis

M. Géniaux, A. Taïeb, G. Chêne, 1995, The Lancet.

[Chronic urticaria and toxocara canis infection. A case-control study].

M. Géniaux, A. Taïeb, G. Chêne, 1996, Annales de dermatologie et de venereologie.

Predictive value of Toxoplasma gondii antibody titres on the occurrence of toxoplasmic encephalitis in HIV‐infected patients

R. Salamon, B. Luft, P. Morlat, 1996, AIDS.

Long‐term survival in patients with advanced immunodeficiency

S J Pocock, B G Gazzard, B. Gazzard, 1997, AIDS.

Nutritional Advice in Older Patients at Risk of Malnutrition during Treatment for Chemotherapy: A Two-Year Randomized Controlled Trial

J. Durrieu, I. Bourdel-Marchasson, N. Houédé, 2014, PloS one.

New insights on the genetic etiology of Alzheimer’s and related dementia

Nick C Fox, Catherine A. Macleod, W. M. van der Flier, 2020 .

Efficacy and Tolerance of High-Dose Inhaled Ipratropium Bromide vs. Terbutaline in Intubated Premature Human Neonates

R. Marthan, D. Breilh, G. Chêne, 2006, Neonatology.

Dendritic cell‐based therapeutic vaccine elicits polyfunctional HIV‐specific T‐cell immunity associated with control of viral load

Rodolphe Thiébaut, Geneviève Chêne, Karolina Palucka, 2014, European journal of immunology.

Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

S. Lees, D. Watson-Jones, M. Belson, 2020, Trials.

Randomized Trial of Vaccines for Zaire Ebola Virus Disease.

S. Lees, D. Watson-Jones, P. Piot, 2022, The New England journal of medicine.

Correction to: Partnership for Research on Ebola VACcination (PREVAC): protocol of a randomized, double-blind, placebo-controlled phase 2 clinical trial evaluating three vaccine strategies against Ebola in healthy volunteers in four West African countries

D. Watson-Jones, Y. Yazdanpanah, J. Neaton, 2021, Trials.

Viral load as a primary outcome in human immunodeficiency virus trials: a review of statistical analysis methods.

H Jacqmin-Gadda, H. Jacqmin-Gadda, R. Salamon, 2001, Controlled clinical trials.

Progression to AIDS or Death as Endpoints in HIV Clinical Trials

H. Fleury, F. Raffi, C. Leport, 2001, HIV clinical trials.

Prognostic factors of combined viral load and CD4+ cell count responses under triple antiretroviral therapy, Aquitaine cohort, 1996-1998.

D. Neau, P. Morlat, F. Dabis, 2001 .

Analysis of left-censored longitudinal data with application to viral load in HIV infection.

D Commenges, H Jacqmin-Gadda, R Thiébaut, 2000, Biostatistics.

TT virus infection during chronic hepatitis C

P. Couzigou, H. Fleury, D. Ekouevi, 2000, American Journal of Gastroenterology.

Enrolling study personnel in Ebola vaccine trials: from guidelines to practice in a non-epidemic context

Y. Yazdanpanah, C. Levy-marchal, A. Beavogui, 2019, Trials.

coagulant than heparin in patients undergoing PTCA

P. Morlat, G. Chêne, V. Guérin, 2018 .

High Level of Plasmatic von Willebrand Factor Limits the Bleeding Time in Thrombopenic HIV-Infected Patients

P. Morlat, G. Chêne, V. Guérin, 1995, Thrombosis and Haemostasis.

Evaluation of the VERSANT HCV RNA 3.0 Assay for Quantification of Hepatitis C Virus RNA in Serum

H. Fleury, G. Chêne, P. Trimoulet, 2002, Journal of Clinical Microbiology.

Effect of transmitted drug resistance on virological and immunological response to initial combination antiretroviral therapy for HIV (EuroCoord-CHAIN joint project): a European multicohort study.

David Dunn, Kholoud Porter, Rodolphe Thiébaut, 2011, The Lancet. Infectious diseases.

Prognosis of patients treated with cART from 36 months after initiation, according to current and previous CD4 cell count and plasma HIV-1 RNA measurements

Ross J. Harris, J. Sterne, A. Mocroft, 2009, AIDS.

Plasma RNA Viral Load in Human Immunodeficiency Virus Type 2 Subtype A and Subtype B Infections

F. Brun-Vézinet, D. Robertson, D. Descamps, 2002, Journal of Clinical Microbiology.

Long‐term evolution of CD4 count in patients with a plasma HIV RNA persistently <500 copies/mL during treatment with antiretroviral drugs

P. Massip, F. Raffi, F. Collin, 2007, HIV medicine.

Definition of virologic response and the type of assay used for quantification of viral load may influence the proportion of responders to antiretroviral therapy. APROCO Study Group.

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2000, Journal of acquired immune deficiency syndromes.

Prognostic value of plasma markers of immune activation in patients with advanced HIV disease treated by combination antiretroviral therapy.

R. Salamon, P. Morlat, G. Chêne, 2001, Clinical immunology.

Modeling changes in CD4-positive T-lymphocyte counts after the start of highly active antiretroviral therapy and the relation with risk of opportunistic infections: the Aquitaine Cohort, 1996-1997.

H. Jacqmin-Gadda, F. Dabis, G. Chêne, 2001, American journal of epidemiology.

Changes in cancer mortality among HIV-infected patients: the Mortalité 2005 Survey.

P. Morlat, D. Costagliola, C. Lewden, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Hospital-based surveillance of HIV infection: Bordeaux, France, 1983-1990. Groupe d'Epidémiologie Clinique du SIDA en Aquitaine (GECSA)

R. Salamon, F. Dabis, G. Chêne, 1991, AIDS.

A national collection of liver tumours: lessons learnt from 6 years of biobanking in France.

B. Clement, F. Degos, G. Chêne, 2009, Cancer letters.

Prevention of the causes of premature illness and death: making it happen.

G. Chêne, 2017, The Lancet. Public health.

Can highly active antiretroviral therapy be interrupted in patients with sustained moderate HIV RNA and > 400 CD4+ cells/µl? Impact on immunovirological parameters

H. Fleury, J. Moreau, J. Viallard, 2005, Journal of medical virology.

Prognostic Factors of Combined Viral Load and CD4+ Cell Count Responses Under Triple Antiretroviral Therapy, Aquitaine Cohort, 1996‐1998

D. Neau, P. Morlat, G. Chêne, 2001, Journal of acquired immune deficiency syndromes.

Immunological markers after long-term treatment interruption in chronically HIV-1 infected patients with CD4 cell count above 400 × 106 cells/l

H. Fleury, J. Moreau, J. Viallard, 2005, AIDS.

Co-trimoxazole in HIV-1 infection

X. Anglaret, G. Chêne, T. Ouassa, 1999, The Lancet.

Investigating the association between cancer and the risk of dementia: Results from the Memento cohort

B. Dubois, F. Pasquier, Y. Béjot, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Guidelines for reporting methodological challenges and evaluating potential bias in dementia research

Carole Dufouil, Cécile Proust-Lima, Rodolphe Thiébaut, 2015, Alzheimer's & Dementia.

Low-frequency drug-resistant HIV-1 and risk of virological failure to first-line NNRTI-based ART: a multicohort European case–control study using centralized ultrasensitive 454 pyrosequencing

Karin J. Metzner, Huldrych F. Günthard, E. Nicastri, 2014, The Journal of antimicrobial chemotherapy.

HIV-Infected Adults With a CD4 Cell Count Greater Than 500 Cells/mm3 on Long-Term Combination Antiretroviral Therapy Reach Same Mortality Rates as the General Population

C. Katlama, M. Dupon, P. Morlat, 2007, Journal of acquired immune deficiency syndromes.

Causes of death in HIV-infected women: persistent role of AIDS. The 'Mortalité 2000 & 2005' Surveys (ANRS EN19).

P. Morlat, D. Costagliola, C. Lewden, 2010, International journal of epidemiology.

Pretreatment CD4 Cell Slope and Progression to AIDS or Death in HIV-Infected Patients Initiating Antiretroviral Therapy—The CASCADE Collaboration: A Collaboration of 23 Cohort Studies

Jim Young, Kholoud Porter, Abdel Babiker, 2010, PLoS medicine.

An International Collaboration To Standardize HIV-2 Viral Load Assays: Results from the 2009 ACHIEV2E Quality Control Study

G. Gottlieb, M. Wainberg, F. Brun-Vézinet, 2011, Journal of Clinical Microbiology.

Polymorphism of the Human Immunodeficiency Virus Type 2 (HIV-2) Protease Gene and Selection of Drug Resistance Mutations in HIV-2-Infected Patients Treated with Protease Inhibitors

F. Brun-Vézinet, F. Mammano, G. Peytavin, 2005, Journal of Clinical Microbiology.

F. Raffi, C. Leport, B. Spire, 2004, AIDS care.

Failure to achieve immunological recovery in HIV-infected patients with clinical and virological success after 10 years of combined ART: role of treatment course

R. Salamon, F. Brun-Vézinet, C. Katlama, 2017, The Journal of antimicrobial chemotherapy.

F. Raffi, M. Carrieri, C. Protopopescu, 2007, Quality of Life Research.

Comparative Effectiveness of Initial Antiretroviral Therapy Regimens: ACTG 5095 and 5142 Clinical Trials Relative to ART-CC Cohort Study

Ross J. Harris, R. Haubrich, J. Sterne, 2011, Journal of acquired immune deficiency syndromes.

The Incidence of AIDS-De fi ning Illnesses at a Current CD 4 Count ≥ 200 Cells / μ L in the Post – Combination Antiretroviral Therapy Era

B. Gazzard, A. Mocroft, O. Kirk, 2013 .

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial

C. Charpentier, C. Katlama, C. Fagard, 2012, Journal of acquired immune deficiency syndromes.

P. Morlat, D. Costagliola, C. Lewden, 2004 .

Determinants of clinical progression in antiretroviral‐naïve HIV‐infected patients starting highly active antiretroviral therapy. Aquitaine Cohort, France, 1996–2002

R. Salamon, D. Neau, P. Morlat, 2005, HIV medicine.

Prospective Cohort Study of the Effect of Pregnancy on the Progression of Human Immunodeficiency Virus Infection

P. Morlat, F. Dabis, G. Chêne, 1995 .

Developing a multidisciplinary network for clinical research on HIV infection: the EuroCoord experience

O. Kirk, C. Sabin, G. Chêne, 2012 .

Pregnancy may be followed by an inflexion of the immune reconstitution in HIV‐infected women who receive antiretroviral drugs before conception

C. Leport, C. Lewden, G. Chêne, 2008, HIV medicine.

CD4:CD8 Ratio and CD8 Count as Prognostic Markers for Mortality in Human Immunodeficiency Virus–Infected Patients on Antiretroviral Therapy: The Antiretroviral Therapy Cohort Collaboration (ART-CC)

J. Sterne, P. Reiss, T. Sterling, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Role of Baseline HIV-1 DNA Level in Highly-Experienced Patients Receiving Raltegravir, Etravirine and Darunavir/Ritonavir Regimen (ANRS139 TRIO Trial)

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2013, PloS one.

Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen

C. Charpentier, F. Brun-Vézinet, C. Katlama, 2010, AIDS.

Incidence of primary opportunistic infections in two human immunodeficiency virus-infected French clinical cohorts.

R. Salamon, K. Freedberg, Y. Yazdanpanah, 2001, International journal of epidemiology.

Incidence and Determinants of Severe Morbidity among HIV-Infected Patients from Rio De Janeiro, Brazil, 2000–2010

F. Bozza, V. Veloso, B. Grinsztejn, 2014, Antiviral therapy.

Risk factors for coronary heart disease in patients treated for human immunodeficiency virus infection compared with the general population.

D. Arveiler, J. Ruidavets, P. Amouyel, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Is long‐term virological response related to CCR5 Δ32 deletion in HIV‐1‐infected patients started on highly active antiretroviral therapy?

C. Katlama, F. Raffi, C. Leport, 2010, HIV medicine.

Pyrimethamine for primary prophylaxis of toxoplasmic encephalitis in patients with human immunodeficiency virus infection: a double-blind, randomized trial. ANRS 005-ACTG 154 Group Members. Agence Nationale de Recherche sur le SIDA. AIDS Clinical Trial Group.

R. Salamon, B. Luft, P. Morlat, 1996, The Journal of infectious diseases.

Adjuvant therapy with pegylated interferon alfa-2b (36 months) versus low-dose interferon alfa-2b (18 months) in melanoma patients without macrometastatic nodes: an open-label, randomised, phase 3 European Association for Dermato-Oncology (EADO) study.

A. Hauschild, H. Pehamberger, M. Landthaler, 2013, European journal of cancer.

Personalized prediction of progression in pre‐dementia patients based on individual biomarker profile: A development and validation study

J. Molinuevo, C. Dufouil, G. Chêne, 2021, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Malignant degeneration of perineal endometriosis in episiotomy scar, case report and review of the literature

M. Canis, G. Mage, G. Chêne, 2006, International Journal of Gynecologic Cancer.

Cellular HIV-1 DNA quantification and short-term and long-term response to antiretroviral therapy.

C. Charpentier, B. Masquelier, F. Raffi, 2011, The Journal of antimicrobial chemotherapy.

Higher HIV-1 DNA associated with lower gains in CD4 cell count among patients with advanced therapeutic failure receiving optimized treatment (ANRS 123--ETOILE).

C. Fagard, C. Rouzioux, G. Chêne, 2010, The Journal of antimicrobial chemotherapy.

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV

P. Morlat, C. Rouzioux, Y. Lévy, 2012, AIDS.

Phase I study of a candidate vaccine based on recombinant HIV-1 gp160 (MN/LAI) administered by the mucosal route to HIV-seronegative volunteers: the ANRS VAC14 study.

H. Hocini, G. Chêne, O. Launay, 2008, Vaccine.

Is nevirapine-based therapy discontinuation in hepatitis C co-infected patients a more important mortality determinant than hypersensitivity.

F. Raffi, C. Lewden, G. Chêne, 2008, AIDS.

Opportunistic infections as causes of death in HIV-infected patients in the HAART era in France

P. Morlat, D. Costagliola, C. Lewden, 2005, Scandinavian journal of infectious diseases.

Predictive factors of intensive care unit admission in patients with haematological malignancies and pneumonia

D. Gruson, G. Chêne, G. Gbikpi-Benissan, 2004, Intensive Care Medicine.

Noninvasive continuous positive airway pressure in neutropenic patients with acute respiratory failure requiring intensive care unit admission

J. Reiffers, D. Gruson, G. Chêne, 2000, Critical Care Medicine.

Gender and incidence of dementia in the Framingham Heart Study from mid-adult life

P. Wolf, C. Dufouil, R. Au, 2015, Alzheimer's & Dementia.

Transmitted drug resistance in French HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, G. Peytavin, 2013, AIDS.

Concordance between HIV-2 genotypic coreceptor tropism predictions based on plasma RNA and proviral DNA

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2013, AIDS.

Randomized clinical trial of sacral nerve stimulation for refractory constipation

A. Leroi, F. Zerbib, F. Mion, 2017, The British journal of surgery.

Screening for Chlamydia trachomatis, Neisseria gonorrhoeae, and Mycoplasma genitalium should it be integrated into routine pregnancy care in French young pregnant women?

G. Chêne, J. Horovitz, J. Asselineau, 2015, Diagnostic microbiology and infectious disease.

Chlamydia trachomatis in subfertile couples undergoing an in vitro fertilization program: a prospective study.

G. Chêne, A. Papaxanthos-Roche, C. Bébéar, 2006, European journal of obstetrics, gynecology, and reproductive biology.

R. Salamon, C. Huët, X. Anglaret, 2001, Journal of acquired immune deficiency syndromes.

A Phylogenetic Analysis of Human Immunodeficiency Virus Type 1 Sequences in Kiev: Findings Among Key Populations

C. Morrison, P. Vanhems, A. Kamali, 2017, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Group and individual cognitive therapies in Alzheimer's disease: the ETNA3 randomized trial

B. Dubois, H. Amièva, F. Pasquier, 2015, International Psychogeriatrics.

Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013.

Anne M Johnson, A. Mocroft, O. Kirk, 2015, Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin.

Validity and Performance of Blood Biomarkers for Alzheimer Disease to Predict Dementia Risk in a Large Clinic-Based Cohort

C. Annweiler, F. Pasquier, K. Bennys, 2022, Neurology.

Changes in the peripheral blood mtDNA levels in naive patients treated by different nucleoside reverse transcriptase inhibitor combinations and their association with subsequent lipodystrophy.

V. Calvez, G. Chêne, L. Cotte, 2007, AIDS research and human retroviruses.

ASSESSMENT OF EARLY CHANGES IN SPECTRAL DOMAIN-OPTICAL COHERENCE TOMOGRAPHY AFTER INITIATION OF TREATMENT WITH INTRAVITREAL AFLIBERCEPT (EYLEA) OVER A 12-WEEK PERIOD FOR PATIENTS WITH NEOVASCULAR AGE-RELATED MACULAR DEGENERATION: A Multicenter French Study (START).

E. Souied, J. Korobelnik, S. Wolf, 2020, Retina.

Long-term evolution and determinants of renal function in HIV-infected patients who began receiving combination antiretroviral therapy in 1997-1999, ANRS CO8 APROCO-COPILOTE.

F. Raffi, C. Leport, J. Rossert, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Long-Term Evolution and Determinants of Renal Function in HIV-Infected Patients Who Began Receiving Combination Antiretroviral Therapy in 1997 – 1999 , ANRS CO 8 APROCO-COPILOTE

F. Raffi, C. Leport, J. Rossert, 2009 .

CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era

P. Vanhems, A. Phillips, N. Pantazis, 2010, AIDS.

Biases in observational studies of the effect of prenatal treatment for congenital toxoplasmosis.

R. Salamon, R. Gilbert, L. Salmi, 2006, European journal of obstetrics, gynecology, and reproductive biology.

Salvage Therapy with Amprenavir, Lopinavir and Ritonavir 200 Mg/D or 400 Mg/D in HIV-Infected Patients in Virological Failure

F. Clavel, G. Chêne, C. Droz, 2003, Antiviral therapy.

Impact of discontinuation of initial protease inhibitor therapy on further virological response in a cohort of human immunodeficiency virus-infected patients.

B. Masquelier, M. Dupon, F. Raffi, 2002, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Impact of gag genetic determinants on virological outcome to boosted lopinavir-containing regimen in HIV-2-infected patients

C. Charpentier, F. Brun-Vézinet, D. Descamps, 2013, AIDS.

Assessment of Plasma Total Tau Level as a Predictive Biomarker for Dementia and Related Endophenotypes

C. DeCarli, C. Dufouil, A. Beiser, 2019, JAMA neurology.

Methodological issues in the use of composite endpoints in clinical trials: examples from the HIV field

Abdel Babiker, Rodolphe Thiébaut, Andrew Phillips, 2010, Clinical trials.

Subjective cognitive and non‐cognitive complaints and brain MRI biomarkers in the MEMENTO cohort

M. Chupin, C. Annweiler, F. Pasquier, 2020, Alzheimer's & dementia.

Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

Olivier Rouaud, Carole Dufouil, Jean-François Dartigues, 2017, Alzheimer's Research & Therapy.

Adjunctive corticosteroid therapy in pediatric severe sepsis: many unsolved questions.

G. Chêne, F. Leclerc, S. Leteurtre, 2011, Pediatric critical care medicine : a journal of the Society of Critical Care Medicine and the World Federation of Pediatric Intensive and Critical Care Societies.

Revised Framingham Stroke Risk Profile to Reflect Temporal Trends

R. D'Agostino, P. Wolf, R. Vasan, 2017, Circulation.

Optimal priming of poxvirus vector (NYVAC)-based HIV vaccine regimens for T cell responses requires three DNA injections. Results of the randomized multicentre EV03/ANRS VAC20 Phase I/II Trial

S. McCormack, D. Montefiori, R. Gottardo, 2020, PLoS pathogens.

Prognostic value of cross-sectional anthropometric indices on short-term risk of mortality in human immunodeficiency virus-infected adults in Abidjan, Côte d'Ivoire.

R. Salamon, F. Dabis, K. Castetbon, 2001, American journal of epidemiology.

Decline in locomotor functions over time in HIV-infected patients

F. Dabis, C. Greib, G. Chêne, 2014, AIDS.

Inequalities by educational level in response to combination antiretroviral treatment and survival in HIV-positive men and women in Europe

O. Kirk, M. Egger, F. Dabis, 2017 .

Changes in CD4+ cell count and the risk of opportunistic infection or death after highly active antiretroviral treatment

D. Neau, F. Dabis, J. Moreau, 1998, AIDS.

Hospital-based surveillance of HIV infection: Epidemiological trends in BOrdeaux, France, 1983–1989

R. Salamon, F. Dabis, G. Chêne, 2013, European Journal of Epidemiology.

CD4+ lymphocyte count and plasma HIV RNA levels in a survey of 1602 HIV-infected patients in Bordeaux, France, 1996-1997. Groupe d'Epidemiologie Clinique da SIDA en Aquitaine.

D. Neau, J. Moreau, D. Malvy, 1998, AIDS (London).

Tobacco addiction and HIV infection: toward the implementation of cessation programs. ANRS CO3 Aquitaine Cohort.

J. Ragnaud, M. Dupon, F. Dabis, 2007, AIDS patient care and STDs.

Intensification of Antiretroviral Therapy through Addition of Enfuvirtide in Naive HIV-1-Infected Patients with Severe Immunosuppression Does Not Improve Immunological Response: Results of a Randomized Multicenter Trial (ANRS 130 Apollo)

C. Charpentier, C. Fagard, Y. Yazdanpanah, 2012, Antimicrobial Agents and Chemotherapy.

Immunoblot Profile as Predictor of Toxoplasmic Encephalitis in Patients Infected with Human Immunodeficiency Virus

J. Miro, B. Luft, P. Morlat, 2001, Clinical Diagnostic Laboratory Immunology.

Non-AIDS causes of death and immunodeficiency ( 40 characters )

C. Sabin, A. Walker, V. Rondeau, 2012 .

Epidemiological and clinical usefulness of HIV/AIDS cohort studies: towards a global collaboration.

G. Chêne, 2007, Enfermedades infecciosas y microbiologia clinica.

Analysis of Undetectable HIV RNA Using Survival Analysis: Results Must Be Interpreted Carefully

H. Jacqmin-Gadda, R. Thiébaut, G. Chêne, 2003, HIV clinical trials.

Severe Morbidity According to Sex in the Era of Combined Antiretroviral Therapy: The ANRS CO3 Aquitaine Cohort

D. Neau, P. Morlat, F. Dabis, 2014, PloS one.

High frequency of poor locomotor performance in HIV-infected patients

F. Dabis, C. Greib, G. Chêne, 2011, AIDS.

Importance of Baseline Prognostic Factors With Increasing Time Since Initiation of Highly Active Antiretroviral Therapy: Collaborative Analysis of Cohorts of HIV-1-Infected Patients

Anne M Johnson, A. Trkola, J. Sterne, 2007, Journal of acquired immune deficiency syndromes.

[Effect of dapsone on survival in HIV infected patients: a meta- analysis of finished trials].

R. Salamon, L. Salmi, G. Chêne, 2000, Revue d'epidemiologie et de sante publique.

Bivariate linear mixed models using SAS proc MIXED

Daniel Commenges, Hélène Jacqmin-Gadda, Rodolphe Thiébaut, 2002, Comput. Methods Programs Biomed..

p53 protein expression in grade II astrocytomas: immunohistochemical study of 100 cases with long-term follow-up.

A. Rougier, G. Kantor, G. Chêne, 1998, Pathology, research and practice.

Number of deaths among HIV-infected adults in France in 2000, three-source capture–recapture estimation

P. Morlat, D. Costagliola, C. Lewden, 2006, Epidemiology and Infection.

Correlations of Soluble Interleukin-2 and Tumor Necrosis Factor Type II Receptors with Immunologic and Virologic Responses Under HAART

R. Salamon, P. Morlat, G. Chêne, 2002, Journal of Clinical Immunology.

Association of Alzheimer’s related genotypes with cognitive decline in multiple domains: results from the Three-City Dijon study

M. Glymour, P. Amouyel, C. Dufouil, 2015, Molecular Psychiatry.

Remote preenrollment checking of consent forms to reduce nonconformity

G. Chêne, V. Journot, S. Couffin‐Cadiergues, 2013, Clinical trials.

HIV infection and tobacco smoking behaviour: prospects for prevention? ANRS CO3 Aquitaine Cohort, 2002.

D. Neau, F. Dabis, E. Lazaro, 2006, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

All-cause mortality in treated HIV-infected adults with CD4 5500/mm compared with the general population: evidence from a large European observational cohort collaborationy

A. Mocroft, O. Kirk, M. Egger, 2022 .

Bivariate Longitudinal Model For The Analysis Of The Evolution Of Hiv Rna And Cd4 Cell Count In Hiv Infection Taking Into Account Left Censoring Of Hiv Rna Measures

H. Jacqmin-Gadda, C. Katlama, P. Morlat, 2003, Journal of biopharmaceutical statistics.

Withholding Primary Pneumocystis Pneumonia Prophylaxis in Virologically Suppressed Patients With Human Immunodeficiency Virus: An Emulation of a Pragmatic Trial in COHERE

M. Zwahlen, A. Mocroft, O. Kirk, 2020, Clinical Infectious Diseases.

[Risk factors of the occurrence of cerebral toxoplasmosis in patients with HIV infection. Definition of indications of primary prevention. Proposals of the Toxoplasmosis and other protozoan infections Group. Coordinated action N.5 - 1996 February].

P. Ambroise‐Thomas, C. Katlama, F. Derouin, 1996, Presse medicale.

Older age at retirement is associated with decreased risk of dementia

M. Glymour, C. Dufouil, A. Alpérovitch, 2014, European Journal of Epidemiology.

Mechanisms of early virologic failure in antiretroviral-naive patients starting protease inhibitor-containing regimens: the APROVIR Study.

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2002, The Journal of infectious diseases.

A new endpoint definition improved clinical relevance and statistical power in a vaccine trial.

Rodolphe Thiébaut, Geneviève Chêne, Ahmadou Alioum, 2009, Journal of clinical epidemiology.

Cytochrome 2B6 polymorphism and efavirenz‐induced central nervous system symptoms : a substudy of the ANRS ALIZE trial

M. Loriot, P. Morlat, G. Chêne, 2017, HIV medicine.

Comparison of 2 regimens that include interferon-alpha-2a plus ribavirin for treatment of chronic hepatitis C in human immunodeficiency virus-coinfected patients.

D. Neau, J. Ragnaud, M. Dupon, 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

Survival and prognosis of women with invasive cervical cancer according to age.

G. Chêne, J. Brun, C. Hocké, 2003, Gynecologic oncology.

Women and HIV infection: a cohort study of 483 HIV‐infected women in Bordeaux, France, 1985–1991

J. Ragnaud, M. Dupon, P. Morlat, 1992 .

Cognitive and imaging markers in non-demented subjects attending a memory clinic: study design and baseline findings of the MEMENTO cohort

B. Dubois, J. Pariente, M. Chupin, 2017, Alzheimer's Research & Therapy.

[Major statistical software usable in epidemiology].

L. Letenneur, R. Salamon, L. Salmi, 1998, Revue d'epidemiologie et de sante publique.

Prognostic score of short-term survival in HIV-infected patients admitted to medical intensive care units

P. Morlat, G. Chêne, G. Hilbert, 2001, International journal of STD & AIDS.

Mortality in a cohort of HIV-infected adults started on a protease inhibitor-containing therapy: standardization to the general population.

F. Raffi, C. Leport, C. Lewden, 2001, Journal of acquired immune deficiency syndromes.

Reply to comment on 'pharmacokinetics of etravirine, raltegravir and darunavir/ritonavir in treatment experienced patients'

C. Katlama, C. Fagard, Y. Yazdanpanah, 2011 .

Salvage therapy with amprenavir, lopinavir and ritonavir is durably potent in HIV-infected patients in virological failure: 1-year results

F. Clavel, G. Chêne, A. Taburet, 2007, AIDS.

Low Genetic Barrier to Large Increases in HIV-1 Cross-Resistance to Protease Inhibitors during Salvage Therapy

C. Charpentier, F. Clavel, G. Chêne, 2006, Antiviral therapy.

The ALBI trial: a randomized controlled trial comparing stavudine plus didanosine with zidovudine plus lamivudine and a regimen alternating both combinations in previously untreated patients infected with human immunodeficiency virus.

G. Chêne, L. Cotte, J. Molina, 1999, The Journal of infectious diseases.

Diabetes-Associated Dementia Risk and Competing Risk of Death in the Three-City Study.

C. Dufouil, C. Berr, E. Frison, 2019, Journal of Alzheimer's disease : JAD.

Brain MRI markers and dropout in a longitudinal study of cognitive aging

M. Glymour, C. Dufouil, C. Tzourio, 2012, Neurology.

Satisfaction with care in HIV-infected patients treated with long-term follow-up antiretroviral therapy: the role of social vulnerability

J. Ragnaud, F. Raffi, C. Protopopescu, 2012, AIDS care.

Sex differences in HIV-1 viral load and TNF-alpha plasmatic level?

P. Morlat, G. Chêne, E. Peuchant, 1999, AIDS (London).

Will biomarker-based diagnosis of Alzheimer’s disease maximize scientific progress? Evaluating proposed diagnostic criteria

A. Brickman, J. Manly, C. Dufouil, 2018, European Journal of Epidemiology.

How Traumatic Brain Injury History Relates to Brain Health MRI Markers and Dementia Risk: Findings from the 3C Dijon Cohort

F. Crivello, C. Dufouil, C. Tzourio, 2023, Journal of Alzheimer's disease : JAD.

Interferon‐gamma with peginterferon alpha‐2a and ribavirin in nonresponder patients with chronic hepatitis C (ANRS HC16 GAMMATRI)

P. Couzigou, P. Marcellin, G. Chêne, 2013, Journal of gastroenterology and hepatology.

Group and individual cognitive therapies in Alzheimer ’ s disease : the ETNA 3 randomized trial

B. Dubois, H. Amièva, F. Pasquier, 2016 .

First-line sunitinib in type I and II papillary renal cell carcinoma (PRCC): SUPAP, a phase II study of the French Genito-Urinary Group (GETUG) and the Group of Early Phase trials (GEP).

A. Ravaud, B. Escudier, S. Oudard, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

IgE serum level: a prognostic marker for AIDS in HIV-infected adults?

R. Salamon, P. Morlat, G. Chêne, 1998, The Journal of allergy and clinical immunology.

Time-updated CD4+ T lymphocyte count and HIV RNA as major markers of disease progression in naive HIV-1-infected patients treated with a highly active antiretroviral therapy: the Aquitaine cohort, 1996-2001.

Hélène Jacqmin-Gadda, Roger Salamon, Rodolphe Thiébaut, 2003, Journal of acquired immune deficiency syndromes.

Randomized Multicenter Trial ( ANRS 130 Immunological Response : Results of a Immunosuppression Does Not Improve HIV-1-Infected Patients with Severe through Addition of Enfuvirtide in Naive Intensification of Antiretroviral Therapy

C. Charpentier, Y. Yazdanpanah, F. Raffi, 2013 .

Mechanism of Virologic Failure After Substitution of a Protease Inhibitor by Nevirapine in Patients With Suppressed Plasma HIV‐1 RNA

B. Masquelier, D. Neau, G. Chêne, 2001, Journal of acquired immune deficiency syndromes.

Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?

J. Sterne, A. Sabin, A. Mocroft, 2018, HIV medicine.

Ribavirin plasma concentration predicts sustained virological response to peginterferon Alfa 2a plus ribavirin in previously treated HCV-HIV-coinfected patients.

D. Breilh, D. Neau, J. Ragnaud, 2009, Journal of acquired immune deficiency syndromes.

Presence of numerous stop codons in HIV-1 reverse transcriptase proviral DNA sequences from patients with virological response to HAART

F. Brun-Vézinet, B. Masquelier, F. Raffi, 2006, AIDS.

Prognosis of HIV-1 infected drug naïve patients starting potent antiretroviral therapy. ART Cohort Collaboration

J. Sterne, M. Egger, R. Hogg, 2002 .

CD4 T cell decline following HIV seroconversion in individuals with and without CXCR4-tropic virus

Anne M Johnson, C. Morrison, P. Vanhems, 2017, The Journal of antimicrobial chemotherapy.

HIV-induced immune deficiency is associated with a higher risk of hepatocarcinoma, ANRS CO3 Aquitaine Cohort, France, 1998-2008.

D. Neau, P. Morlat, F. Dabis, 2011, Journal of hepatology.

Clinical research infrastructures and networks in France: report on the French ECRIN workshop.

J. Pignon, C. Libersa, G. Chêne, 2005, The´rapie (Paris).

P643 Causes of liver related death in HIV-infected patients in France: mortality 2005 Survey

P. Morlat, D. Costagliola, C. Lewden, 2007 .

Physical activity, biomarkers of brain pathologies and dementia risk: Results from the Memento clinical cohort

J. Pariente, C. Dufouil, R. David, 2023, Alzheimer's & dementia : the journal of the Alzheimer's Association.

Public health institutes and the fight against climate change

M. Pascal, R. Phalkey, G. Chêne, 2022, The Lancet Public Health.

Predictors of CD4 cell recovery following initiation of antiretroviral therapy among HIV‐1 positive patients with well‐estimated dates of seroconversion

C. Morrison, P. Vanhems, A. Kamali, 2017, HIV medicine.

R57K Polymorphism in the Human Immunodeficiency Virus Type 1 Protease as Predictor of Early Virological Failure in a Cohort of Antiretroviral-Naive Patients Treated Mostly with a Nelfinavir-Containing Regimen

B. Masquelier, F. Raffi, B. Spire, 2003, Antimicrobial Agents and Chemotherapy.

Intermittent viremia during first-line, protease inhibitors-containing therapy: significance and relationship with drug resistance.

B. Masquelier, H. Fleury, F. Raffi, 2005, Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology.

Prolonged medically recorded treatment interruptions among HIV-infected patients on highly active antiretroviral therapy with controlled viremia: when physicians have to juggle patient negotiation and guidelines.

C. Katlama, F. Raffi, M. Carrieri, 2010, Journal of acquired immune deficiency syndromes.

Lipodystrophy and nucleoside analogue therapy in HIV-infected patients: important question, few valid answers.

S. Suissa, G. Chêne, M. Savès, 2000, Journal of acquired immune deficiency syndromes.

CO-TRIMOXAZOLE IN HIV-1 INFECTION. AUTHORS' REPLY

M. Molyneux, G. Maartens, T. Taylor, 1999 .

Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer.

F. Penault-Llorca, Y. Bignon, F. Mishellany, 2009, European journal of cancer.

An Example of Nonrandom Missing Data for Hepatitis C Virus Status in a Prognostic Study Among HIV-Infected Patients

H. Jacqmin-Gadda, L. Cuzin, C. Leport, 2004, HIV clinical trials.

Duedari N, Bierling P. Presence of cross-reactive antibody between human immunodeficiency virus (HIV) and platelet glycoproteins by HIV-related immune thrombocytopenic purpura

P. Morlat, G. Chêne, V. Guérin, 2018 .

Alternative methods to analyse the impact of HIV mutations on virological response to antiviral therapy

D. Commenges, D. Breilh, D. Neau, 2008 .

Diabetes Mellitus and Cognition

M. Chupin, C. Annweiler, F. Pasquier, 2021, Neurology.

The Dementias Platform UK (DPUK) Data Portal

Alan J. Thomas, J. Gallacher, P. Matthews, 2019, bioRxiv.

Cardiovascular risk profile in women and dementia.

C. Dufouil, S. Seshadri, G. Chêne, 2014, Journal of Alzheimer's Disease.

TEMPORAL TRENDS IN DEMENTIA INCIDENCE IN THE FRAMINGHAM STUDY

P. Wolf, C. Dufouil, R. Au, 2014, Alzheimer's & Dementia.

Triple-class virologic failure in HIV-infected patients undergoing antiretroviral therapy for up to 10 years.

A. Mocroft, H. Günthard, R. Paredes, 2010, Archives of internal medicine.

C. Katlama, C. Fagard, Y. Yazdanpanah, 2009, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

P. Couzigou, P. Marcellin, G. Chêne, 2010, Journal of medical virology.

A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa.

R. Salamon, H. Ahiboh, C. Rouzioux, 2015, The New England journal of medicine.

Long-Term Efficacy and Safety of Raltegravir, Etravirine, and Darunavir/Ritonavir in Treatment-Experienced Patients: Week 96 Results From the ANRS 139 TRIO Trial

C. Charpentier, C. Katlama, C. Fagard, 2012, Journal of acquired immune deficiency syndromes.

Comparative cost-effectiveness analysis of sacral anterior root stimulation for rehabilitation of bladder dysfunction in spinal cord injured patients.

G. Chêne, A. Bénard, J. Vignes, 2013, Neurosurgery.

Older age at retirement is associated with decreased risk of dementia

M. Glymour, C. Dufouil, A. Alpérovitch, 2014, European Journal of Epidemiology.

Effect of HCV infection on cause-specific mortality after HIV seroconversion, before and after 1997.

C. Sabin, R. Geskus, M. Prins, 2013, Gastroenterology.

Evidence-based medicine: basic principles

G. Chêne, M. Savès, L. Wittkop, 2017, La Revue du praticien.

All-cause mortality in treated HIV-infected adults with CD4 ≥500/mm3 compared with the general population: evidence from a large European observational cohort collaboration.

A. Mocroft, O. Kirk, A. d’Arminio Monforte, 2012, International journal of epidemiology.

Complexities of cerebral small vessel disease, blood pressure, and dementia relationship: new insights from genetics

V. Gudnason, O. Lopez, H. Jacqmin-Gadda, 2023, medRxiv.

Intention-to-treat vs. on-treatment analyses of clinical trial data: experience from a study of pyrimethamine in the primary prophylaxis of toxoplasmosis in HIV-infected patients. ANRS 005/ACTG 154 Trial Group.

R. Salamon, B. Luft, C. Leport, 1998, Controlled clinical trials.

CD4 decline in seroconverter and seroprevalent individuals in the precombination of antiretroviral therapy era

P. Vanhems, A. Phillips, N. Pantazis, 2010, AIDS.

Long-term mortality in HIV-positive individuals virally suppressed for >3 years with incomplete CD4 recovery.

J. Sterne, O. Kirk, A. d’Arminio Monforte, 2014, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

New insights into the genetic etiology of Alzheimer’s disease and related dementias

Nick C Fox, Pavel P. Kuksa, W. M. van der Flier, 2022, Nature Genetics.

Effect of intermittent interleukin-2 therapy on CD4+ T-cell counts following antiretroviral cessation in patients with HIV

P. Morlat, C. Rouzioux, Y. Lévy, 2012, AIDS.

Higher rates of AIDS during the first year of antiretroviral therapy among migrants: the importance of tuberculosis

J. Sterne, T. Sterling, M. May, 2013, AIDS.

Cost-Effectiveness Analysis of Lopinavir/Ritonavir Monotherapy Versus Standard Combination Antiretroviral Therapy in HIV-1 Infected Patients with Viral Suppression in France (ANRS 140 DREAM)

B. Spire, G. Chêne, P. Girard, 2019, PharmacoEconomics - open.

Good response to lopinavir/ritonavir-containing antiretroviral regimens in antiretroviral-naive HIV-2-infected patients

B. Autran, J. Ananworanich, K. Ruxrungtham, 2009, AIDS.

Comparison of dysplasia profiles in stimulated ovaries and in those with a genetic risk for ovarian cancer.

F. Mishellany, C. Pomel, G. Chêne, 2009, European journal of cancer.